Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline.

Shintaro IwamaTomoko KobayashiYoshinori YasudaTakayuki OkujiMasaaki ItoMasahiko AndoXin ZhouAyana YamagamiTakeshi OnoueYohei KawaguchiTakashi MiyataMariko SugiyamaHiroshi TakagiDaisuke HagiwaraHidetaka SugaRyoichi BannoTetsunari HaseMasahiro MoriseKeiko WakaharaKenji YokotaMasashi KatoNaoki NishioChie TanakaKazushi MiyataAtsushi OguraTakanori ItoTsunaki SawadaTomoya ShimokataKaoru NiimiFumiharu OhkaMasatoshi IshigamiMomokazu GotohNaozumi HashimotoRyuta SaitoHitoshi KiyoiHiroaki KajiyamaYuichi AndoHideharu HibiMichihiko SoneMasashi AkiyamaYasuhiro KoderaHiroshi Arima

Published in: The Journal of clinical endocrinology and metabolism (2021)

This study showed that the incidence of thyroid-irAEs was high and not negligible after PD-1/CTLA-4-Abs treatment even in patients negative for ATAs at baseline.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
risk factors
patient reported outcomes
patient reported